These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

204 related articles for article (PubMed ID: 7604812)

  • 1. Hematological features of patients with myelodysplastic syndromes associated with a chromosome 5q deletion.
    Lewis S; Oscier D; Boultwood J; Ross F; Fitchett M; Rack K; Abrahamson G; Buckle V; Wainscoat JS
    Am J Hematol; 1995 Jul; 49(3):194-200. PubMed ID: 7604812
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A prognostic impact of separation of refractory cytopenia with multilineage dysplasia and 5q- syndrome from refractory anemia in primary myelodysplastic syndrome.
    Cermák J; Michalová K; Brezinová J; Zemanová Z
    Leuk Res; 2003 Mar; 27(3):221-9. PubMed ID: 12537974
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Refractory cytopenia with multilineage dysplasia: further characterization of an 'unclassifiable' myelodysplastic syndrome.
    Rosati S; Mick R; Xu F; Stonys E; Le Beau MM; Larson R; Vardiman JW
    Leukemia; 1996 Jan; 10(1):20-6. PubMed ID: 8558932
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Myeloid disorders with deletion of 5q as the sole karyotypic abnormality: the clinical and pathologic spectrum.
    Washington LT; Doherty D; Glassman A; Martins J; Ibrahim S; Lai R
    Leuk Lymphoma; 2002 Apr; 43(4):761-5. PubMed ID: 12153162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome following haematopoietic cell transplantation in patients with myelodysplasia and del (5q) karyotypes.
    Stewart B; Verdugo M; Guthrie KA; Appelbaum F; Deeg HJ
    Br J Haematol; 2003 Dec; 123(5):879-85. PubMed ID: 14632779
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Application of megakaryocytic morphology in diagnosing 5q- syndrome.
    Thiede T; Engquist L; Billström R
    Eur J Haematol; 1988 Nov; 41(5):434-7. PubMed ID: 3208866
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Myelodysplastic syndromes (MDS). Aspects of hematopathologic diagnosis].
    Schmitt-Graeff A; Mattern D; Köhler H; Hezel J; Lübbert M
    Pathologe; 2000 Jan; 21(1):1-15. PubMed ID: 10663664
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Less apoptosis in patients with 5q-syndrome than in patients with refractory anemia.
    Washington LT; Jilani I; Estey E; Albitar M
    Leuk Res; 2002 Oct; 26(10):899-902. PubMed ID: 12163050
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chromosome analyses in patients with myelodysplastic syndromes: correlation with bone marrow histopathology and prognostic significance.
    Werner M; Maschek H; Kaloutsi V; Choritz H; Georgii A
    Virchows Arch A Pathol Anat Histopathol; 1992; 421(1):47-52. PubMed ID: 1636249
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
    Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
    Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Results of chromosome studies and their relation to morphology, course, and prognosis in 120 patients with de novo myelodysplastic syndrome.
    Suciu S; Kuse R; Weh HJ; Hossfeld DK
    Cancer Genet Cytogenet; 1990 Jan; 44(1):15-26. PubMed ID: 2293879
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prognostic implications of morphology and karyotype in primary myelodysplastic syndromes.
    Jacobs RH; Cornbleet MA; Vardiman JW; Larson RA; Le Beau MM; Rowley JD
    Blood; 1986 Jun; 67(6):1765-72. PubMed ID: 3708160
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical management of myelodysplastic syndromes with interstitial deletion of chromosome 5q.
    Nimer SD
    J Clin Oncol; 2006 Jun; 24(16):2576-82. PubMed ID: 16735711
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Re-evaluation of refractory anemia with excess blasts in transformation.
    Ohyashiki K; Nishimaki J; Shoji N; Miyazawa K; Kimura Y; Ohyashiki JH
    Leuk Res; 2001 Nov; 25(11):933-9. PubMed ID: 11597728
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Bone marrow morphology predicts additional chromosomal abnormalities in patients with myelodysplastic syndrome with del(5q).
    Geyer JT; Verma S; Mathew S; Wang YL; Racchumi J; Espinal-Witter R; Subramaniyam S; Knowles DM; Orazi A
    Hum Pathol; 2013 Mar; 44(3):346-56. PubMed ID: 22995330
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cytogenetic studies in 112 cases of untreated myelodysplastic syndromes.
    Solé F; Prieto F; Badia L; Woessner S; Florensa L; Caballin MR; Coll MD; Besses C; Sans-Sabrafen J
    Cancer Genet Cytogenet; 1992 Nov; 64(1):12-20. PubMed ID: 1458444
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Leukemic transformation in patients with 5Q- and additional abnormalities.
    Larripa I; Acevedo S; Palau Nagore MV; Bengiò R; Mondini N; Slavutsky I
    Haematologica; 1991; 76(5):363-7. PubMed ID: 1806438
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Factors influencing survival in myelodysplastic syndromes in a Brazilian population: comparison of FAB and WHO classifications.
    Lorand-Metze I; Pinheiro MP; Ribeiro E; de Paula EV; Metze K
    Leuk Res; 2004 Jun; 28(6):587-94. PubMed ID: 15120935
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hematologic and clinical features of patients with chromosome 5 monosomy or deletion (5q).
    Brusamolino E; Orlandi E; Morra E; Bernasconi P; Pagnucco G; Colombo A; Lazzarino M; Bernasconi C
    Med Pediatr Oncol; 1988; 16(2):88-94. PubMed ID: 3352540
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cytogenetic and molecular diagnosis of chromosome 5 deletions in myelodysplasia.
    Westbrook CA; Hsu WT; Chyna B; Litvak D; Raza A; Horrigan SK
    Br J Haematol; 2000 Sep; 110(4):847-55. PubMed ID: 11054067
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.